[go: up one dir, main page]

MX2009003815A - Formulaciones farmaceuticas. - Google Patents

Formulaciones farmaceuticas.

Info

Publication number
MX2009003815A
MX2009003815A MX2009003815A MX2009003815A MX2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A MX 2009003815 A MX2009003815 A MX 2009003815A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
active agent
formulation
dissolution
salt
Prior art date
Application number
MX2009003815A
Other languages
English (en)
Inventor
Dennis Y Lee
Yi Gao
R Ju Tzuchi
Nicole Nguyen
Hauiliang Wu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2009003815A publication Critical patent/MX2009003815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una formulación de liberación modificada que comprende un agente activo en una matriz de polímero hidrofílico, en donde el agente activo es una sal de ácido fonolfíbrico en donde la velocidad de liberación de la formulación en una disolución in vitro es sustancialmente independiente de la concentración iónica del medio de disolución.
MX2009003815A 2006-10-12 2007-10-12 Formulaciones farmaceuticas. MX2009003815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12
PCT/US2007/081267 WO2008046052A1 (en) 2006-10-12 2007-10-12 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MX2009003815A true MX2009003815A (es) 2009-09-07

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003815A MX2009003815A (es) 2006-10-12 2007-10-12 Formulaciones farmaceuticas.

Country Status (14)

Country Link
EP (1) EP2081563A1 (es)
JP (1) JP2010506855A (es)
KR (1) KR20090119959A (es)
CN (1) CN101677981A (es)
AU (1) AU2007307641A1 (es)
CA (1) CA2672686A1 (es)
CO (1) CO6160302A2 (es)
EA (1) EA200900531A1 (es)
EC (1) ECSP099251A (es)
IL (1) IL198160A0 (es)
MX (1) MX2009003815A (es)
SG (1) SG175570A1 (es)
WO (1) WO2008046052A1 (es)
ZA (1) ZA200902488B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2285357T3 (da) * 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1829541A1 (en) * 2002-12-17 2007-09-05 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP5114382B2 (ja) * 2005-04-08 2013-01-09 アボット・ラボラトリーズ フェノフィブリン酸および／またはそれの塩を含む経口医薬製剤

Also Published As

Publication number Publication date
SG175570A1 (en) 2011-11-28
WO2008046052A1 (en) 2008-04-17
CN101677981A (zh) 2010-03-24
KR20090119959A (ko) 2009-11-23
JP2010506855A (ja) 2010-03-04
EA200900531A1 (ru) 2009-12-30
CA2672686A1 (en) 2008-04-17
IL198160A0 (en) 2009-12-24
AU2007307641A1 (en) 2008-04-17
ECSP099251A (es) 2009-06-30
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27
CO6160302A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
ATE303793T1 (de) Pharmazeutische komposition für verlängerte/langanhaltende freisetzung eines therapeutisch aktiven wirkstoffes
CY1121952T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
AR062321A1 (es) Sistema de liberacion controlada y metodo para fabricarlo
EA200870379A1 (ru) Фармацевтическая композиция с замедленным высвобождением на основе системы высвобождения, включающей кислоторастворимый полимер и ph-зависимый полимер
WO2008137758A3 (en) Amino acid lipids and uses thereof
PL2148703T3 (pl) Nowy środek umożliwiający wysalanie substancji czynnych w opatrunkach zawierających co najmniej jedną substancję tłuszczową
WO2009060608A1 (ja) Ｓｄｆ－１を含有してなる徐放性組成物
WO2006116718A3 (en) Pharma-informatics system
ATE515260T1 (de) Stabile nanokapselsysteme für die verabreichung von wirkstoffen
EP2120878A4 (en) DOSAGE FORM WITH TWO OR MORE PHARMACEUTICAL ACTIVITIES IN DIFFERENT PHYSICAL FORMS
WO2010068281A3 (en) Contact lens drug delivery device
MX2009013019A (es) Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.
PT2043600T (pt) Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas
MX2009004439A (es) Composicion de ibuprofeno.
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
MX2009003815A (es) Formulaciones farmaceuticas.
MX2009006447A (es) Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato.
CY2019021I1 (el) Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων
WO2012092486A3 (en) Modified release benzimidazole formulations
EP2558077A4 (en) ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION WITH FENOFIBRIC ACID AND AN ALKALIZING AGENT
BRPI0810878A2 (pt) Partículas à base de polieletrólitos e de princípio ativo de liberação modificada e formulações farmacêuticas contendo estas partículas.
ITRM20050393A1 (it) Sistema di rilascio controllato di sostanze farmacologicamente attive, processo di preparazione e impieghi in campo medico.
FR2967576B1 (fr) Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release

Legal Events

Date Code Title Description
FA Abandonment or withdrawal